Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Amarillo Biosciences Signs Deal with CytoPharm of Taiwan

publication date: Mar 25, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Amarillo Biosciences, Inc. has entered a second license and supply agreement with CytoPharm, Inc. of Taiwan for Amarillo Biosciences’ low-dose interferon. Under this agreement, CytoPharma will conduct tests to support the use of low-dose interferon in animals (swine, poultry, cattle) to treat or prevent animal diseases. CytoPharm will seek approval of the drug in Taiwan and China. CytoPharm is already conducting a Phase II clinical trial to test whether low-dose interferon can prevent relapse in hepatitis C patients. More details...

Stock Symbol: (OTCBB: AMAR)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners